Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab and Anlotinib in Resectable NSCLC (ALTER-L043)
NCT04846634Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Aug 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of penpulimab and anlotinib in non-small cell lung cancer (NSCLC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
penpulimabanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04846634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04846634.